| 本帖最后由 老马 于 2012-1-13 21:20 编辑 " z3 v, ^  \$ w" N
 9 D, K; m$ u6 ~; u* \) A爱必妥和阿瓦斯丁的比较
 ; m# K# H# ]$ H7 M1 G
  % L2 j0 a4 j$ ]9 E3 z" Z& c. B http://cancergrace.org/lung/2008/08/30/bms099-os-neg/; A9 ^2 D! g9 C4 B+ g
 
   ' \8 |1 M! @$ ~* B% Z
   / \6 u3 J. s+ {' B( \http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
 7 z7 A- T- s& N7 A% A) h==================================================
 Z0 C! }( ^/ f8 }  V% KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 i5 }; C  s. v  P7 x
 Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* |2 U8 K  _: M: N% l
 Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
 / P" v4 [# Q5 l% H) `1 p
   |